CG Oncology, Inc. (NASDAQ:CGON) is highlighted as one of the Best Small-Cap Growth Stocks to Buy Right Now, with a Buy rating and $75 price target by H.C. Wainwright. The company’s drug Cretostimogene for treating BCG-unresponsive high-risk non-muscle invasive bladder cancer shows strong results, with data from ongoing studies expected by the end of 2025. CG Oncology is improving drug administration and stability and seeing faster patient enrollment in trials and growing market awareness. The company focuses on developing bladder-sparing therapies for bladder cancer.

Read more at Yahoo Finance: H.C. Wainwright Reiterates a Buy on CG Oncology (CGON), Keeps the PT